The Scopolamine-reversal Paradigm in Rats and Monkeys: the Importance of Computer-assisted Operant-conditioning Memory Tasks for Screening Drug Candidates

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2007 Jul 28

PMID 17657478

Citations 27

Authors

Jerry J Buccafusco

Alvin V Terry Jr

Scott J Webster

Daniel Martin

Elizabeth J Hohnadel

Kristy A Bouchard

Samantha E Warner

Affiliations

Soon will be listed here.

Abstract

Rationale: The scopolamine-reversal model is enjoying a resurgence of interest in clinical studies as a reversible pharmacological model for Alzheimer's disease (AD). The cognitive impairment associated with scopolamine is similar to that in AD. The scopolamine model is not simply a cholinergic model, as it can be reversed by drugs that are noncholinergic cognition-enhancing agents.

Objectives: The objective of the study was to determine relevance of computer-assisted operant-conditioning tasks in the scopolamine-reversal model in rats and monkeys.

Materials And Methods: Rats were evaluated for their acquisition of a spatial reference memory task in the Morris water maze. A separate cohort was proficient in performance of an automated delayed stimulus discrimination task (DSDT). Rhesus monkeys were proficient in the performance of an automated delayed matching-to-sample task (DMTS).

Results: The AD drug donepezil was evaluated for its ability to reverse the decrements in accuracy induced by scopolamine administration in all three tasks. In the DSDT and DMTS tasks, the effects of donepezil were delay (retention interval)-dependent, affecting primarily short delay trials. Donepezil produced significant but partial reversals of the scopolamine-induced impairment in task accuracies after 2 mg/kg in the water maze, after 1 mg/kg in the DSDT, and after 50 microg/kg in the DMTS task.

Conclusions: The two operant-conditioning tasks (DSDT and DMTS) provided data most in keeping with those reported in clinical studies with these drugs. The model applied to nonhuman primates provides an excellent transitional model for new cognition-enhancing drugs before clinical trials.

Citing Articles

Cognitive-Enhancing Effects of Acetylcholine Receptor Agonists in Group-Housed Cynomolgus Monkeys Who Drink Ethanol.

Galbo-Thomma L, Epperly P, Blough B, Landavazo A, Saldana S, Carroll F J Pharmacol Exp Ther. 2023; 389(3):258-267.

PMID: 38135508 PMC: 11125785. DOI: 10.1124/jpet.123.001854.

Improving Visual Working Memory with Cholinergic Deep Brain Stimulation.

Bava J, Wang Z, Bick S, Englot D, Constantinidis C Brain Sci. 2023; 13(6).

PMID: 37371395 PMC: 10296349. DOI: 10.3390/brainsci13060917.

M-selective muscarinic allosteric modulation enhances cognitive flexibility and effective salience in nonhuman primates.

Hassani S, Neumann A, Russell J, Jones C, Womelsdorf T Proc Natl Acad Sci U S A. 2023; 120(18):e2216792120.

PMID: 37104474 PMC: 10161096. DOI: 10.1073/pnas.2216792120.

Dose-Dependent Dissociation of Pro-cognitive Effects of Donepezil on Attention and Cognitive Flexibility in Rhesus Monkeys.

Hassani S, Lendor S, Neumann A, Roy K, Banaie Boroujeni K, Hoffman K Biol Psychiatry Glob Open Sci. 2023; 3(1):68-77.

PMID: 36712561 PMC: 9874073. DOI: 10.1016/j.bpsgos.2021.11.012.

Neuroprosthetics: from sensorimotor to cognitive disorders.

Gupta A, Vardalakis N, Wagner F Commun Biol. 2023; 6(1):14.

PMID: 36609559 PMC: 9823108. DOI: 10.1038/s42003-022-04390-w.

References

Buccafusco J, Terry Jr A, Murdoch P . A computer-assisted cognitive test battery for aged monkeys. J Mol Neurosci. 2002; 19(1-2):179-85. DOI: 10.1007/s12031-002-0030-6. View

Koller G, Satzger W, Adam M, Wagner M, Kathmann N, Soyka M . Effects of scopolamine on matching to sample paradigm and related tests in human subjects. Neuropsychobiology. 2003; 48(2):87-94. DOI: 10.1159/000072883. View

Jones R, Wesnes K, Kirby J . Effects of NMDA modulation in scopolamine dementia. Ann N Y Acad Sci. 1991; 640:241-4. DOI: 10.1111/j.1749-6632.1991.tb00226.x. View

Hao J, Li K, Li K, Zhang D, Wang W, Yang Y . Visual attention deficits in Alzheimer's disease: an fMRI study. Neurosci Lett. 2005; 385(1):18-23. DOI: 10.1016/j.neulet.2005.05.028. View

Bartus R . Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav. 1978; 9(6):833-6. DOI: 10.1016/0091-3057(78)90364-7. View

Rossor M, Iversen L . Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Br Med Bull. 1986; 42(1):70-4. DOI: 10.1093/oxfordjournals.bmb.a072101. View

Van Dam D, De Deyn P . Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov. 2006; 5(11):956-70. DOI: 10.1038/nrd2075. View

de Bruin N, Pouzet B . Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav. 2006; 85(1):253-60. DOI: 10.1016/j.pbb.2006.08.007. View

Bain J, Prendergast M, Terry Jr A, Arneric S, Smith M, Buccafusco J . Enhanced attention in rhesus monkeys as a common factor for the cognitive effects of drugs with abuse potential. Psychopharmacology (Berl). 2003; 169(2):150-60. DOI: 10.1007/s00213-003-1483-1. View

10.

Misane I, Ogren S . Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology. 2003; 28(2):253-64. DOI: 10.1038/sj.npp.1300024. View

11.

Molchan S, Mellow A, Lawlor B, Weingartner H, Cohen R, Cohen M . TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl). 1990; 100(1):84-9. DOI: 10.1007/BF02245795. View

12.

Wellstein A, Pitschner H . Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1988; 338(1):19-27. DOI: 10.1007/BF00168807. View

13.

Buccafusco J, Jackson W, Stone J, Terry A . Sex dimorphisms in the cognitive-enhancing action of the Alzheimer's drug donepezil in aged Rhesus monkeys. Neuropharmacology. 2003; 44(3):381-9. DOI: 10.1016/s0028-3908(02)00378-7. View

14.

Riedel W, Hogervorst E, Leboux R, Verhey F, van Praag H, Jolles J . Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl). 1995; 122(2):158-68. DOI: 10.1007/BF02246090. View

15.

Thompson S, Lanctot K, Herrmann N . The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf. 2004; 3(5):425-40. DOI: 10.1517/14740338.3.5.425. View

16.

Duka T, Ott H, Rohloff A, Voet B . The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Psychopharmacology (Berl). 1996; 123(4):361-73. DOI: 10.1007/BF02246647. View

17.

Heise G . Behavioral methods for measuring effects of drugs on learning and memory in animals. Med Res Rev. 1984; 4(4):535-58. DOI: 10.1002/med.2610040405. View

18.

Preston G, Ward C, Lines C, Poppleton P, Haigh J, Traub M . Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine. Psychopharmacology (Berl). 1989; 98(4):487-94. DOI: 10.1007/BF00441947. View

19.

Ray P, Meador K, Loring D, Zamrini E, Yang X, Buccafusco J . Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol. 1992; 5(2):72-7. DOI: 10.1177/002383099200500203. View

20.

Taffe M, Weed M, GOLD L . Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Brain Res Cogn Brain Res. 1999; 8(3):203-12. DOI: 10.1016/s0926-6410(99)00021-x. View